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األعراض السريرية و املخربية للمرضى اليمنيني املصابني مبرض الذئبة 
احلمراء اجلهازية
ح�صن عبد �لوهاب �ل�صماحي, جنالء �صيف �هلل, يحيى �لعزي
abstract: Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by 
multi-systemic involvement. This is the first study undertaken to determine the relationships between serological 
marker positivity and age, gender, signs and symptoms, risk factors and the treatment of SLE in Yemen. Methods: 
We investigated the cases of 149 patients with SLE admitted to Al-Thawra Hospital in Sana’a city between November 
2009 and November 2010. Of the 149 patients, females represented 75.2% and males, 24.8%. Results: The most 
frequent presenting signs and symptoms were fatigue (84.6%), fever (81.9%), arthropathy (81.2%), anaemia (64.4%), 
photosensitivity (54.4%), renal involvement (53%), malar rash (52.3%), and alopecia (49%). Antinuclear antibodies 
(ANA) were detected in 95.3% of the patients and were associated significantly with most clinical presentations, 
except weight loss, hypertension and serositis. Anti-ds deoxyribonucleic acid (anti-dsDNA) was detected in 59.7% 
of the patients, and was associated significantly with fever and fatigue. Anti-Smith (anti-Sm) antibodies were 
detected in 27.5% of the patients, but were not significantly associated with all clinical presentations. Social stress 
was the most important risk factor for inducing SLE, with an odds ratio (OR) of 6.0, followed by common exposure 
to sunlight (OR = 2.2). Conclusion: In this study, SLE was more prevalent among females and young adults. The 
clinical presentation was characterised by a high incidence of fatigue and fever, and a low incidence of oral ulcers and 
serositis. ANA was associated with most clinical presentations except weight loss, hypertension, and serositis. Anti-
dsDNA antibodies were most frequently associated with fever, fatigue and hypertension. There was no significant 
association of the anti-Sm antibodies with any clinical presentations. 
Keywords: Systemic lupus erythematosus (SLE); Autoantibodies; Antinuclear antibodies (ANA); Anti-ds DNA; 
Anti-Smith Antibodies (Anti-Sm); Yemen.
امللخ�ص: الهدف: مر�س �لذئبه �حلمر�ء هي عبارة عن مر�س مناعي ذ�تي مزمن يتميز باإ�صابة �أكرث من جهاز من �أجهزة ج�صم �الن�صان. تعترب هذه �لدر��صة 
هي �الأوىل يف �ليمن لتحديد �لعالقات بي �لعالمات �مل�صلية �الإيجابية و�ل�صن و�جلن�س وعالمات و�أعر��س هذ� �ملر�س وعو�مل �خلطر و�لعالج لهذ� �ملر�س. 
149 مري�صا يعانون من مر�س �لذئبة �حلمر�ء وذلك مب�صت�صفى �لثورة يف مدينة �صنعاء؛ مثلت �الإناث %75.2 و�لذكور 24.8%  �لطريقة: متت در��صة 
من كل �ملر�صى يف �لدر��صة. �لنتائج: كانت �لعالمات و�الأعر��س �الأكرث �صيوعا هي �لتعب )%84.6(، و�حلمى )%81.9(, �العتالل �ملف�صلي )81.2%(, 
�حل�صا�صية لل�صوء )%54.4(, تاأثر �لكلى )%53.0(, وطفح وجني )%52.3(، فقد�ن �لوزن وفقد�ن و ت�صاقط �ل�صعر )%49.0(. مت �لك�صف عن �الأج�صام 
%95.3 من �ملر�صى و كانت مرتبطة ب�صكل كبري مع معظم �الأعر��س �ل�رشيرية فيما عد� فقد�ن �لوزن و�رتفاع �صغط �لدم و �لتهاب  �مل�صادة للنو�ة يف 
�مل�صلية. مت �لك�صف عن �الأج�صام �مل�صادة للحم�س �لنووي �لريبي يف نحو %59.7 من �ملر�صى, وكانت لديهم �أعر��س حمى وتعب وحمى. وجدت �أ�صد�د 
�صميث يف %27.5 من �ملر�صى, ولكنها مل تكن مرتبطة باأي مر�س. وكان �لتوتر �الجتماعي عامل �خلطر �الأكرث �أهمية يف �إحد�ث مر�س �لذئبة �حلمر�ء بن�صبة 
ترجيحية تبلغ %6.2 تليها �لتعر�س الأ�صعة �ل�صم�س بن�صبة ترجيحية تبلغ %2.2. �خلال�صة: كان مر�س �لذئبه �حلمر�ء �أكرث �نت�صار� بي �الإناث و�صغار 
�لبالغي. متيزت �الأعر��س �ل�رشيرية بن�صبة عالية من عر�صي �لتعب و�حلمى, وحدوث منخف�س لقرح �لفم و�اللتهاب �مل�صلي. �رتبطت �الأج�صام �مل�صادة للنو�ة 
مع معظم �الأعر��س �ل�رشيرية با�صتثناء فقد�ن �لوزن, �رتفاع �صغط �لدم, و �اللتهاب �مل�صلي. و�رتبطت �الأج�صام �مل�صادة للحم�س �لنووي �لريبي مع معظم 
�مل�صابي باحلمى, و�لتعب, و�رتفاع �صغط �لدم. ومل يكن هناك �رتباط كبري الأ�صد�د �صميث مع �أي من �الأعر��س �ل�رشيرية. 
مفتاح الكلمات: مر�س �لذئبه �حلمر�ء؛ �الأج�صام �مل�صادة للنو�ة؛ �الأج�صام �مل�صادة للحم�س �لنووي �لريبي؛ �أ�صد�د �صميث؛ �ليمن.
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Advances in Knowledge 
- This study provides new information about systemic lupus erythematosus (SLE) in Yemen, including the ratio of males to females 
affected, as well as the antibody-marker association ratio with clinical manifestations, symptoms and signs. This study also highlights 
the potential risk factors that contribute to increasing a person’s likelihood of developing SLE.  
- Such information is important in recommending a policy for the treatment and management of SLE in Yemen, especially as there are 
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Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by multisystem microvascular inflammation 
with the generation of numerous auto-antibodies, 
particularly antinuclear antibodies (ANA). SLE 
can affect persons of both sexes, all ages, and all 
ethnic groups. However, more than 90% of new 
patients presenting with SLE are women in their 
childbearing years.1 SLE is a disease that affects 
multiple systems and its symptoms vary widely. 
The multiple organ damage in SLE is due to the 
production of auto-antibodies, which include 
auto-antibodies to antigens of the brain, renal 
and vascular tissues, ribosomes, nuclear antigens 
and phospholipids. Intracranial vascular lesions 
(vasculitis and thrombosis) and inflammation have 
been related to the local release of cytokines.1 In 
addition, recent data have suggested that both renal 
and neuropsychiatric involvement negatively affects 
the overall five-year survival rate. However, the 
neuropsychiatric involvement did not change for 
the 10-year survival rate, in spite of the fact that the 
involvement of the nervous system in SLE remains 
poorly understood.2
SLE affects the immune system, thus reducing 
the body’s ability to prevent and fight infection. 
In addition, many of the drugs used to treat SLE 
also impair the functioning of the immune system, 
thereby further reducing the patient’s ability to fight 
infection. The most common infections involve 
the respiratory tract, urinary tract and skin; these 
infections do not require hospitalisation if they are 
treated promptly. Other opportunistic infections—
particularly salmonella, herpes zoster and Candida 
infections—are more common in patients with SLE 
because of altered immune status.3‒5 Fatigue in SLE 
is probably multifactorial and has been related not 
only to disease activity, but also to complications 
such as anaemia or hypothyroidism.
SLE is known to differ among people with 
different racial, geographical and socioeconomic 
backgrounds. Asia encompasses people of many 
sociocultural backgrounds with diverse ethnic 
groups—broadly Orientals in East and Southeast 
Asia, Indians in South Asia and Arabs in the 
Middle East. It has been shown that race is a major 
predictor of the clinical manifestations of SLE, 
laboratory and serological tests, and disease-related 
morbidity. Comparative studies have shown that 
SLE has a higher prevalence, and higher morbidity 
and mortality rates, in the Oriental population than 
among Caucasians.3‒5 
Due to a lack of national epidemiological 
research, the incidence and prevalence of SLE in 
Middle Eastern and Arab countries, have only 
recently been studied. There have been no previous 
studies on SLE in Yemen; therefore, this study aims 
to determine the relationships between serological 
marker positivity and age, gender, signs and 
symptoms, risk factors and the treatment of SLE in 
Yemen. 
Methods 
This study was carried out over a period of one 
year from November 2009 to November 2010. The 
study was approved by the Department of Medical 
Microbiology & Clinical Immunology of the Faculty 
of Medicine & Health Sciences at Sana'a University, 
Yemen. A consent form was completed by each 
participant.
A total of 149 Yemeni patients, admitted to 
medical wards and/or attending medical clinics at 
Al-Thawra Hospital in Sana’a city, were enrolled 
in this study. All patients fulfilled four or more of 
the revised American College of Rheumatology 
(ACR) criteria for the diagnosis of SLE.6 The 
specifically-designed questionnaires were analysed 
retrospectively for relevant data such as patients’ 
age, sex, their clinical manifestation at presentation 
and during follow-up, and their exposure to 
possible risk factors of SLE. The treatments, either 
initially or during their follow-up appointments, 
currently no other studies of this disease in Yemen. 
- Moreover, SLE is likely to be a growing problem in Yemen that could go unrecognised if new information about the disease is not 
promoted within the national medical community.
Application to Patient Care
- The findings of this research could contribute to the formulation of a treatment and management policy for SLE, including, ultimately, 
the management of its complications and sequelae. However, further studies are required to form a more comprehensive understanding 
of the risk factors and characteristics of SLE in Yemen.
Clinical and Laboratory Manifestations of Yemeni Patients with Systemic Lupus Erythematosus
e82 | SQU Medical Journal, February 2014, Volume 14, Issue 1
were also recorded, as well as any complications. 
Laboratory data include leukopaenia (white blood 
cells <4000/mm9), anaemia (haemoglobin <11 gm\
dL) and thrombocytopaenia (platelets <100,000/
mm9). Laboratory data also included Raised 
erythrocyte sedimentation rate, positive ANA, 
positive rheumatoid factor, high anti-DNA and anti-
Sm antibody. ANA was measured by two different 
methods: indirect immunofluorescence (IIF) and 
enzyme-linked immunosorbent assay (ELISA), 
anti-ds deoxyribonucleic acid (anti-dsDNA) and 
anti-Smith (anti-Sm) antibodies were measured 
by the ELISA method (INOVA Diagnostics Kits, 
San Diego, California, USA). Lupus nephritis was 
confirmed by renal biopsy, which was graded 
according to the World Health Organization 
classification of II, III, IV or V.6 Photosensitivity 
was recognised by specific skin lesions induced by 
sunlight. The odds ratio (OR) for the association of 
auto-antibody markers with clinical presentations 
of SLE, and their Cornfield 95% confidence limits, 
were calculated by the analysis of a single table 
(the simplest contingency table being the 2 x 2 
table). Furthermore, the Chi-square (X2) value for 
statistical significance was calculated using Yates’ 
continuity correction. However Fisher's exact test 
was employed for small cell sizes with a two-tailed 
probability value (P), using the Epi-Info Version 
6 software (Centers for Disease Control and 
Prevention, Atlanta, Georgia, USA). The various 
medications used in patient treatment ranged 
from non-steroidal anti-inflammatory drugs 
(NSAIDs), hydroxychloroquine and steroids, to 
intermittent cyclophosphamide with intravenous 
methylprednisolone in lupus nephritis. Warfarin 
was the anticoagulant used in the cases of venous 
thrombosis.
Results
The mean age of patients was 28.8 years (range 
11–57 years). Females had a higher SLE prevalence 
Table 1: Gender and age distribution among systemic 
lupus erythematosus patients attending Al-Thawra 




n (%) n (%) n (%)
<15 2 (5.4) 15 (13.4) 17 (11.4)
16–25 9 (24.3) 38 (33.9) 47 (1.5)
26–35 16 (43.2) 32 (28.6) 48 (32.2)
36–45 8 (21.6) 21 (18.8) 29 (19.5)
>45 2 (5.4) 6 (5.3) 8 (5.4)























Table 2: The relationship between clinical manifestations and 
presence of antinuclear antibodies (ANA) auto-antibodies 










114 (93.4) 9.8 3.1–32 20.2 <0.0001
Fatigue
(n = 126)
117 (92.8) 10 3.1–33.4 19.9 <0.0001
Weight loss 
(n = 73)
67 (91.7) 2.3 0.75–7.3 1.9 0.16
Arthropathy 
(n = 121)




75 (94.9) 5.11 1.5–19.4 7.5 0.006
Malar rash 
(n = 78)
75 (96.2) 7.3 1.86–33.2 10.1 0.001
Alopecia 
(n = 73)




78 (96.2) 8 2.1–36.5 11.34 0.0007
Serositis 
(n = 14)
8 (57.1) 0.14 0.04–0.55 9.8 0.003*
Oral ulcers 
(n = 16)




46 (83.6) 0.6 0.2–1.8 1.02 0.03*
ANA = antinuclear antibodies; OR = odds ratio; CI = 95% confidence interval; 
*Fisher's exact test P value; Significant result χ2 ≥ 3.84, P <0.05.
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than males, with a female to male ratio of 3:1. The 
prevalence of SLE was greater in the 16–35 years 
age group [Table 1]. The clinical presentation 
of SLE was characterised by a high incidence of 
fatigue and fever, while there was a low incidence 
of oral ulcers and serositis [Table 5]. The blood 
picture of the patients showed a low prevalence 
of leukopaenia and lymphopaenia, and a high 
prevalence of thrombocytopaenia [Table 5]. Tables 
2, 3 and 4 show the relationship between the auto-
antibody positivity and the clinical symptoms. ANA 
was statistically significant (χ2 >3.9 and P <0.05) 
and associated with most clinical presentations 
(OR 5.1–10.2) except weight loss, hypertension and 
serositis [Table 2]. Anti-dsDNA antibodies, which 
are a specific marker for SLE, showed a statistically 
significant association with fever (OR = 3.12; CI: 
1.2–8.12; X2 = 5.9; P = 0.01); fatigue (OR = 2.7; 
CI: 1–7.4; X2 = 3.84; P = 0.05), and hypertension 
(OR = 2.15; CI: 1.0–4.6; χ2 = 3.84; P = 0.05) [Table 
3]. Anti-Sm antibodies, which are a highly specific 
marker for SLE, were not significantly associated 
with any clinical presentations [Table 4]. Lupus 
nephritis was significantly associated with red 
blood cell (RBC) casts, proteinuria, hyaline casts, 
elevated creatinine levels and hypertension. The 
two main risk factors in Yemeni SLE patients were 
found to be frequent exposure to sunlight (OR 
= 6.0; CI: 2.6–13.9; P <0.0001) and to social and 
mental stress (OR = 2.8; CI: 0.4–9.6; P = 0.04), while 
the use of contraceptives by females was not a risk 
factor (OR = 0.5; CI: 0.1–1.5; P = 0.17). Similarly, 
chewing qat (plant containing an amphetamine-
like stimulant native to the horn of Africa and the 
Arabian Peninsula) was not found to be a risk factor 
for SLE in this study (OR = 0.5; CI: 0.2–0.9; P = 0.01) 
[Table 6]. Table 5 shows the frequencies of clinical 
and laboratory features of SLE among different 
ethnicities compared with the present study. The 
Table 3: The relationship between clinical manifestations 
and presence of ds deoxyribonucleic acid (dsDNA) auto-











79 (64.8) 3.1 1.2–8.12 5.96 0.01
Fatigue 
(n = 126)
80 (63.5) 2.7 1–7.4 3.84 0.05
Weight loss 
(n = 73)
49 (63.4) 1.8 0.9–3.7 2.68 0.1
Arthropathy 
(n = 121)




51 (64.5) 1.5 0.75–3.13 1.23 0.26
Malar rash 
(n = 78)
49 (62.8) 1.3 0.6–2.6 0.41 0.52
Alopecia 
(n = 73)




47 (58) 0.86 0.4–1.74 0.09 0.76
Serositis 
(n = 14)
5 (35.7) 0.34 0.09–1.2 2.76 0.1*
Oral ulcers 
(n = 16)
5 (31.3) 0.34 0.09–1.18 2.69 0.1*
Hypertension 
(n = 55)
39 (71) 2.15 1–4.6 3.84 0.05
OR = odds ratio; CI = 95% confidence interval;
*Fisher's exact test P value; Significant result χ2 ≥ 3.84, P <0.05.
Table 4: The relationship between clinical manifestations 
and presence of anti-Smith antibodies (anti-Sm) auto-










37 (30.3) 2.5 0.75–9.23 1.9 0.16
Fatigue 
(n = 126)
38 (30.2) 2.9 0.75–12.9 2.06 0.15
Weigh loss 
(n = 73)
22 (30.1) 1.3 0.6–2.8 0.27 0.6
Arthropathy 
(n = 121)




20 (25.3) 0.8 0.36–1.7 0.21 0.64
Malar rash 
(n = 78)
25 (32.1) 1.6 0.73–3.6 1.24 0.26
Alopecia 
(n = 73)




22 (27.2) 0.96 0.44–2.1 0.01 0.93
Serositis 
(n = 14)
2 (14.3) 0.4 0.06–2.1 0.72 0.35*
Oral ulcers 
(n = 16)
4 (25) 0.86 0.2–3.1 0.00 1.0
Hypertension 
(n = 55)
15 (27.3) 0.98 0.43–2.2 0.02 0.889
OR = odds ratio; CI = 95% confidence interval; 
*Fisher's exact test P value; Significant result χ2 ≥ 3.84, P <0.05.
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mortality rate in our study was 4.7%; the causes of 
death were pulmonary embolism (2%), septicaemia 
(2%) and disseminated intravascular coagulopathy 
with refractory heart failure (0.7%).
Discussion
The ratio of male patients to female patients in the 
current study was 1:3. This result is in disagreement 
with the results of other studies which have reported 
an even higher prevalence of SLE among females; 
these include male to female ratios of 1:7.2, 1:9 and 
1:9.9.3,7,8
The mean patient age in the present study of 
28.8 years was similar to that reported from Dubai, 
United Arab Emirates (28.9 years)9 and Spain (29 
years).10 The majority of patients (88.6%) were 
adults, while 11.4% were children under 15 years. 
This is similar to the study by Alballa whose patients 
were predominately above 15 years.11 The high rate 
among adults may be related to adult sex hormones 
which play an important role in triggering the 
disease.12
Fatigue, the most common constitutional 
symptom associated with SLE, could be caused 
by active SLE, medications, lifestyle habits or 
concomitant fibromyalgia—or affective disorders. 
Fatigue due to active SLE generally occurs in 
concert with other clinical and laboratory markers.3 
The most frequent clinical symptom among the 
SLE patients in this study was fatigue (84.6%). This 
finding is in contrast to other studies performed 
in Saudi Arabia and Iran, where the frequency 
of fatigue was reported as 9.2%13 and 30.2%,14 
Table 5: Frequencies of clinical and laboratory features of systemic lupus erythematosus among studies of different 
ethnicities compared with the current study
Yemen Saudi 
Arabia7
UAE9 Kuwait18 Lebanon17 Tunis15 Iran14 Spain10 Pakistan3
Year 2010 2009 2008 1998 1999 2004 2008 2004 2004
Number of patients 149 624 151 108 100 100 410 600 196
Mean age 28.8 25.3 28.9 31.5 25 32 30.3 29 31
Male:female ratio 1:3 1:9.8 1:20.5 1:9.8 1:6.1 1:11.5 1:6.6 1:8 1:7.1
Signs and symptoms in %
Fatigue 84.6 42.5 - - - - 30.2 - -
Fever 81.9 30.6 51.0 - - - 63.4 42 -
Arthropathy 81.2 80.4 81.1 87 95 78 65.5 83 38
Photosensitivity 54.4 30.6 43 48 16 53 54.5 41 6
Renal involvement 53.0 47.9 51 37 50 43 47.8 34 33
Malar rash 52.3 47.9 60.3 43 52 63 60.5 54 29
Alopecia 49 - - 44 - - 23.0 81 22
Oral ulcers 10.7 39.1 30.5 33 40 4 27.8 30 19.7
Serositis 9.4 27.4 27.2 - 40 45 38 - 22
Hemolytic anaemia - - 9.9 - 10 6 12.5 8 -
Anaemia 64.4 63.1 44.3 - - - 74.6 19 -
Leucopaenia 28.2 30 53.6 83 17 - 64.5 66 22
Lymphopaenia 36.2 40.3 - - - 50 43.4 82 -
Thrombocytopaenia 44.3 10.9 18.5 26 33 12 44.6 30 26
ANA 95.3 99.7 88 94 87 100 93 99 86
Anti-dsDNA 59.7 80.1 88.7 58 50 56 83 90 74
Anti-Sm 27.5 - 19.7 13 - 61.2 - 12 50
UAE = United Arab Emirates; ANA = antinuclear antibodies; Anti-dsDNA = anti-ds deoxyribonucleic acid; Anti-Sm = anti-Smith antibodies.
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respectively. This could be explained by the fact that 
our questionnaire included fatigue as a potentially 
important symptom of SLE, while questionnaires 
used in previous studies did not consider fatigue to 
be important.
Fever was also common in the patients int this 
study (81.9%), and their temperature usually showed 
diurnal variation—being high in the afternoon and 
evening. The frequency of fever was higher than 
that reported in other studies—in Spain 42% of 
patients studied experienced fever, while in Saudi 
Arabia it was 30%.10,7 
Arthropathy was a common sign (81.2%) in this 
study, and this result is similar to findings reported 
from Dubai (81.1%)9 and Saudi Arabia (80.4%).7 
However, the rates of arthropathy in Yemen were far 
higher than those experienced in Pakistan (38%).3 
Photosensitivity occurred in 54.5% of the current 
study’s patients, which was similar to that reported 
in Tunisia (53%)15 and Iran (54.5%).14 However, 
lower prevalence rates have been reported from 
Pakistan (6%),3 Saudi Arabia (22%)16 and Europe 
(22.9%).8 This difference can be explained by the 
patients’ high exposure to sunlight in this study. 
In this study group, renal involvement of SLE 
was variable in clinical presentation and prognosis, 
ranging from mild asymptomatic proteinuria 
to rapidly progressive glomerulonephritis 
(GN) leading to end-stage renal disease. Renal 
involvement affected 53.3% of the patients. Similar 
findings were reported by studies in Lebanon 
(50%)17 and Dubai (51%),8 but these are in contrast 
to the low frequencies reported in Pakistan (33%)2 
and European countries (27.9%).9 Yemen’s findings 
of similar renal involvement to that of other Arabic 
countries (Lebanon and Dubai) may be due to the 
shared factors (genetic, environmental and dietary) 
that could trigger or control the presentation of the 
disease. 
Malar rash was present in 52.3% of the current 
study’s patients which is similar to findings 
in Lebanon (52%)16 and Spain (54%)9 but is in 
disagreement with the lower prevalence found in 
Pakistan (29%).3 Alopecia occurred in 49% of our 
patients, which is similar to the study in Kuwait 
(44.0%) by Al-Jarallah et al,18 but lower than that 
of Spain (81%), reported by Font et al.10 Oral ulcers 
were less frequent in our study (10.7%) and were of 
similar occurrence to findings from Latin America 
(10.5%)19 but lower than those from Lebanon (40%)17 
and Saudi Arabia (39.1%).7 The present study had 
the lowest incidence of serositis (9.4%) compared to 
studies in Lebanon (45%)17 and in Iran (38%).14 This 
finding could be related to a failure of physicians to 
record the symptoms.
The presence of ANA is a hallmark of 
SLE disease and one of the diagnostic criteria 
established by the ACR. In the present study, the 
prevalence of ANA was 95.3% [Table 5]. Similar 
findings have been reported from Saudi Arabia 
(95%)16 and European countries (96%),8 but an even 
higher prevalence was noted in Tunisia (100%).15 
However, our figure was slightly higher than those 
of India (71.4%),20 Lebanon (87%)17 and Pakistan 
(86%).3 In spite of its apparent importance, some 
researchers have not agreed that ANA is a hallmark 
of SLE disease. Anti-dsDNA antibodies are quite 
specific and diagnostically important for SLE.21 The 
prevalence of circulating anti-dsDNA antibodies in 
Yemeni patients was 59.7% [Table 5]. Very similar 
results have been obtained from Tunisia (56%)15 
and Kuwait (58%),18 but are in contrast to the higher 
frequency found in Saudi Arabia (93%),11 Spain 
(90%)10 and Dubai (88%).9 These differences may 
reflect a variable prevalence of anti-dsDNA in the 
world. In the current study, the prevalence of anti-
Sm antibodies was 27.5% [Table 5] which indicates 
that anti-Sm antibodies are highly specific and of 
considerable diagnostic value for SLE as they appear 
Table 6: The potential risk factors of systemic lupus 
erythematosus among the patients of the current study




























sun light (at 
least 2 hours/
day)
42 (28.2) 2.2 1.1–4.7 5.0 0.02*




14 (12.5) 0.8 0.4–2.0 0.17 0.68
OR = odds ratio; CI = 95% confidence interval.
*Fisher's exact test P value; Significant result χ2 ≥ 3.84, P <0.05.
**The stress assessment was done by the psychiatrists at Al-Thawra Hospital, 
Sana’a city.
†Qat = plant containing amphetamine-like stimulant native to the horn of 
Africa and the Arabian Peninsula.
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almost exclusively in SLE, as reported by Tan et al.22 
Our prevalence is higher than that in Spain (12%)10 
but lower than that in Tunisia (61.2%).15 
The great diversity of clinical manifestations 
in SLE, ranging, for example, from arthritis and 
serositis to life-threatening neuropsychiatric 
manifestations, is accompanied by a high titre 
of auto-antibodies.23 The current study found a 
strong statistical correlation between ANA and 
most clinical manifestations except weight loss, 
serositis and hypertension [Table 2]. There was 
also a significant correlation between anti-dsDNA 
and clinical manifestations such as fever, fatigue 
and hypertension, but no significant correlation 
with weight loss, arthropathy, renal involvement, 
alopecia, malar rash, serositis, oral ulcer and 
photosensitivity [Table 3]. The absence of a 
statistically significant correlation between anti-
dsDNA and renal involvement in our study, even 
though dsDNA is known to be one of the main 
markers of lupus nephritis as described by Raz et 
al.,24 may be related to unknown factors in Yemen 
that need to be clarified. There was no significant 
association between anti-Sm antibodies and most of 
the clinical manifestations in Table 4, except fever, 
as has been confirmed by Hitchon and Peschken.25
Patients with SLE have a complex array of 
abnormalities involving their immune system. A 
history of multiple cytopaenias such as leukopaenia, 
lymphopaenia, anaemia or thrombocytopaenia may 
suggest SLE, among other aetiologies.1,2 In our 
series, anaemia was the most frequently occurring 
haematological abnormality in our patients [Table 
5]. It occurred in about 64.4% of our patients, 
similar to the rate reported in Saudi Arabia (63.1%),7 
but higher than that reported in Spain (19%).10 
Lymphopaenia was present in 36.2% of our patients, 
the same as (30%) in Saudi Arabia,6 but lower 
than the 50% rate in Tunisia15 and 82% rate 
in Spain.10 The low incidence can probably be 
explained by the fact that the immunological 
response of our patients was not typical of the 
disease, in which the auto-antibodies in SLE are 
directed against a wide variety of self-antigens. 
Leukopaenia occurred in 28.2% of our patients. This 
is quite similar to other studies reported by Agrawal 
et al.26 and Al-Arfaj and Khalil,7 but much lower 
than the 83% reported by Al-Jarallah et al.18 and the 
64.6% recorded by Nazarinia et al.14 Our study found 
a high prevalence of thrombocytopaenia (44.3%); 
a similar result was reported in Iran by Nazarinia 
et al.,14 while lower prevalence was reported from 
Tunisia (12%),15 Kuwait (26%)18 and Saudi Arabia 
(10.9%).9 
Erythrocyte sedimentation rate (ESR) is one 
of the major monitoring tests for acute phase 
inflammation because it correlates with increased 
levels of acute phase reactants, in particular 
fibrinogen. In the present study, the frequency of 
ESR was 89.9%. A similar finding was reported in a 
study on Indian children (98.5%) by Agrawal et al.,26 
which is in contrast to studies with low frequency 
in Iran(64.6%)14 and Saudi Arabia (54%).7 This 
difference may be due to many factors that affected the 
ESR result, including the patient’s age, sex, red blood 
count morphology, haemoglobin concentration and 
serum levels of immunoglobulin.27
The mortality rate in our patients was low (4.7%) 
and was somewhat similar to the rates in three 
different studies from Saudi Arabia; 3%,13 4%,11 and 
5.4%.7 This could be attributed to early diagnosis 
and effective treatment in controlling the disease.
The second aim of this study was to examine 
the risk factors that could have influenced the 
occurrence of SLE among our study group, this 
being the first study designed to determine the 
risk factors of contracting SLE in Yemen. Frequent 
exposure to sunlight and stress (social and mental) 
were found to be risk factors in Yemeni SLE 
patients. This might be explained by the fact that 
psychological stress can activate an acute phase 
response, which is part of the innate immune 
inflammatory response; it is also evidence that 
the inflammatory response is contained within 
the stress response, and that stress can induce an 
inflammatory response.28 This study also indicates 
that sunlight, especially ultraviolet B light (290–
320 nm), plays an important role in inducing 
this systemic disease.29 Oral contraceptive pills, 
especially those with high oestrogen doses, may 
provoke flares of SLE.30 In the present study, 
however, no association was discovered between 
oral contraceptives and SLE.
Conclusion
SLE was more prevalent among females and young 
adults. The clinical presentation was characterised 
by a high incidence of fatigue and fever, and a 
low incidence of oral ulcers and serositis. ANA 
Hassan A. Al-Shamahy, Najla H. M. Dhaifallah and Yahya M. Al-Ezzy
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was significantly associated with most clinical 
presentations except weight loss, hypertension 
and serositis. Anti-dsDNA antibodies were a 
specific marker and significantly associated with 
fever, serositis, oral ulcer, fatigue, hypertension 
and arthropathy. Anti-Sm antibodies were highly 
specific markers for SLE and significantly associated 
with oral ulcers. 
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